viewInnoCan Pharma

InnoCan Pharma's CBD-loaded liposomal technology achieves positive test results

The platform enables the targeted injection of hydrogel-cannabinoid-loaded liposomes into the bloodstream or to a specific body part

InnoCan Pharma - InnoCan Pharma Corporation achieves positive results following tests on its cannabidiol (CBD) loaded liposomal platform technology
After a few months of testing, high loading of CBD was achieved

InnoCan Pharma Corporation (CSE:INNO) announced Monday that it has achieved positive results following months of tests on its cannabidiol (CBD) loaded liposomal platform technology.

The platform enables the delivery of cannabinoids by injection of hydrogel-cannabinoid-loaded liposomes into the bloodstream or to a specific body part, the Israeli cannabis company said in a statement.  

The controlled release of CBD (or other cannabinoids) from the liposomes may allow continuous exposure of the patient to the cannabinoid and decreases the variations of CBD concentration in the blood caused by food intake or other physiological conditions. 

READ: Israeli cannabis companies flower on the Canadian Securities Exchange

Moreover, through injection of loaded liposomes, a greater portion of intact CBD can reach its target site, decreasing the total amount of CBD needed to achieve the desired therapeutic effect. The use of the technology is versatile and may be tailored to the development of different cannabinoids, the company said. 

InnoCan conducted the tests in conjunction with the Yissum Research and Development Company, the commercial arm of Hebrew University in Jerusalem. Development efforts and tests for the CBD-loaded liposomes were performed over several months and achieved the following results:

  • High loading of CBD in an amount sufficient for administration of a therapeutic dose.
  • Several types of CBD liposomal formulations were developed having potential of targeting a variety of clinical indications for CBD injection administration.
  • The liposomal formulations may have the potential to enable a controlled-release delivery of injectable CBD.

"This is a significant milestone and creates the basis for the development of therapeutically meaningful new drugs, based on local injection of CBD, that could have greater efficacy and promote the well-being of patients suffering different ailments," said Chezy Barenholz, head of membrane and liposome research lab at the Hebrew University Hadassah Medical School.

InnCan CEO Iris Bincovich added: "These positive first stage results are a powerful demonstration of the value of our partnership with Hebrew University. Continued test success would provide InnoCan with numerous commercial prospects. We anticipate the completion of the next development stage, within 18 to 24 months." 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


Quick facts: InnoCan Pharma

Price: 0.06 CAD

Market: CSE
Market Cap: $8.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...



Full interview: Innocan signs deal with Hebrew university while also signing...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver from Toronto with news the company has signed a deal with the distribution company Active Therapeutics. This agreement allows Innocan to move into the U.K. and Ireland.  Bincovich also told...

on 02/04/2020

2 min read